Related Experiment Video
Updated: Jun 11, 2026

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
Hyperglycosylation is a metabolic driver of Alzheimer's disease
Tara R Hawkinson1,2, Zizhen Liu1,2, Roberto A Ribas1,2
1Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, FL, USA.
Abstract:
Alzheimer's disease (AD) is a devastating neurodegenerative disorder marked by progressive cognitive decline. Metabolic disruptions are widely observed, yet their involvement in the molecular aetiology of AD remains underexplored. Here we identify hyperglycosylation as a driver of AD. Integrating spatial metabolomics, lipidomics and glycomics in transgenic AD mouse models and post-mortem human AD samples, along with advanced spatial isotopic tracing pulse-chase analysis of N-linked glycans, we demonstrate that the conserved phenotype of brain hyperglycosylation is driven by increased glycan biosynthesis. Genetic knockdown of glycan biosynthetic enzymes improves cognitive outcomes in AD mice whereas oral glucosamine supplementation impairs them. A retrospective analysis of electronic health records from patients with AD with varying disease severity shows that glucosamine supplementation is associated with accelerated AD progression and worsened survival. Overall, these results establish hyperglycosylation as a pathological driver of AD and highlight glycan metabolism as an actionable target in the fight against AD.
Related Concept Videos
Alzheimer Disease l: Introduction
Hyperglycemia
Alzheimer Disease ll: Pathophysiology
Proteoglycans
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
